Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.

Small GTPases - 2 Jan 2017

Fields Alan P, Ali Syed A, Justilien Verline, Murray Nicole R

Abstract excerpt

Lung cancer is the leading cause of cancer death in the US with ∼124,000 new cases annually, and a 5 y survival rate of ∼16%. Mutant KRAS-driven lung adenocarcinoma (KRAS LADC) is a particularly prevalent and deadly form of lung cancer. Protein kinase Cι (PKCι) is an oncogenic effector of KRAS that activates multiple signaling pathways that stimulate transformed growth and invasion, and maintain a KRAS LADC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Isoenzymes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplastic Stem Cells

Share to Protein Kinase C

Share to Proto-Oncogene Proteins p21(ras)

Share to Sirolimus

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27245608
DOI: 10.1080/21541248.2016.1194953
PMCID: PMC5331898

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.PMID 27245608Read ↗

Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.Semantic proximity Read ↗

Requirement for PKC Epsilon in Kras-Driven Lung TumorigenesisSemantic proximity Read ↗

PKCε Is Required for KRAS-Driven Lung Tumorigenesis.Semantic proximity Read ↗

Current therapy of KRAS-mutant lung cancer.Semantic proximity Read ↗

Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma.Semantic proximity Read ↗

Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.Semantic proximity Read ↗

Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.Semantic proximity Read ↗

Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.Semantic proximity Read ↗

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.Semantic proximity Read ↗

SIGNATURE-DRIVEN REPURPOSING OF MIDOSTAURIN FOR COMBINATION WITH MEK1/2 AND KRASG12C INHIBITORS IN LUNG CANCERSemantic proximity Read ↗

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.Semantic proximity Read ↗

<i>Map2k4</i> Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor γ2 ExpressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.